School of Health and Behavioural Sciences, University of the Sunshine Coast, Maroochydore, QLD, 4558, Australia.
Sunshine Coast Health Institute, Birtinya, QLD, 4556, Australia.
Parasitol Res. 2022 Mar;121(3):1065-1071. doi: 10.1007/s00436-022-07460-4. Epub 2022 Feb 11.
A recent publication in Parasitology Research by (Old et al. Parasitol Res 120:1077-1090, 2021) raises the topical and often controversial issue of the treatment of wildlife by personnel with little or no formal scientific training (e.g. wildlife carers). In a valuable contribution to the subject, Old and colleagues document a wide range of topical (pour-on) application doses and frequencies of moxidectin (Cydectin®) administered in situ to bare-nosed wombats (Vombatus ursinus) by members of the wildlife carer/treater community in southeast Australia to treat sarcoptic mange disease. This treatment occurred under minor use permits issued by the Australian Pesticides and Veterinary Management Authority (APVMA). These permits do not require veterinary supervision, although carers are registered and are expected to comply with the guidelines of this permit.The prevalence and severity of sarcoptic mange in wildlife is influenced by a variety of factors including mite biology, environmental conditions, population density, animal behaviour and immune susceptibility (Browne et al. Bioscience, 2021). In bare-nosed wombats, combinations of these elements play a substantial role in making the treatment of an already difficult disease more complex. (Moroni et al. Parasit Vectors 13:471, 2020) comment that any pharmacological treatment of free-ranging wildlife must consider these factors when assessing their feasibility and implications, especially in the context of emerging drug resistance and potential long-term ecological impacts. As individuals with significant interest in sarcoptic mange and representing a range of professional research and veterinary expertise, we see value in providing expert commentary on this issue.
最近在寄生虫学研究杂志上发表的一篇文章（Old 等人，寄生虫学研究 120:1077-1090, 2021）提出了一个热门且经常有争议的问题，即非专业人士（例如野生动物护理人员）对野生动物进行治疗。在对该主题的有价值的贡献中，Old 及其同事记录了澳大利亚东南部野生动物护理/治疗人员在裸鼻袋熊（Vombatus ursinus）身上局部（喷洒）应用莫昔克丁（Cydectin®）的各种剂量和频率，以治疗疥螨病。这种治疗是在澳大利亚农药和兽医管理局（APVMA）颁发的少量使用许可证下进行的。这些许可证不需要兽医监督，尽管护理人员已注册并预计将遵守该许可证的指南。寄生虫学研究 120:1077-1090, 2021）提出了一个热门且经常有争议的问题，即非专业人士（例如野生动物护理人员）对野生动物进行治疗。在对该主题的有价值的贡献中，Old 及其同事记录了澳大利亚东南部野生动物护理/治疗人员在裸鼻袋熊（Vombatus ursinus）身上局部（喷洒）应用莫昔克丁（Cydectin®）的各种剂量和频率，以治疗疥螨病。这种治疗是在澳大利亚农药和兽医管理局（APVMA）颁发的少量使用许可证下进行的。这些许可证不需要兽医监督，尽管护理人员已注册并预计将遵守该许可证的指南。寄生虫学研究 120:1077-1090, 2021）提出了一个热门且经常有争议的问题，即非专业人士（例如野生动物护理人员）对野生动物进行治疗。在对该主题的有价值的贡献中，Old 及其同事记录了澳大利亚东南部野生动物护理/治疗人员在裸鼻袋熊（Vombatus ursinus）身上局部（喷洒）应用莫昔克丁（Cydectin®）的各种剂量和频率，以治疗疥螨病。这种治疗是在澳大利亚农药和兽医管理局（APVMA）颁发的少量使用许可证下进行的。这些许可证不需要兽医监督，尽管护理人员已注册并预计将遵守该许可证的指南。野生动物中疥螨病的流行和严重程度受多种因素影响，包括螨虫生物学、环境条件、种群密度、动物行为和免疫易感性（Browne 等人，生物科学，2021 年）。在裸鼻袋熊中，这些因素的组合在使已经难以治疗的疾病变得更加复杂方面起着重要作用。（Moroni 等人，寄生虫载体 13:471, 2020）评论说，任何对自由放养野生动物的药物治疗都必须考虑到这些因素，以评估其可行性和影响，特别是在出现抗药性和潜在的长期生态影响的情况下。作为对疥螨病有浓厚兴趣并代表一系列专业研究和兽医专业知识的个人，我们认为对这一问题发表专家意见是有价值的。
